Daridorexant hydrochloride
- CAS No.
- 1792993-84-0
- Chemical Name:
- Daridorexant hydrochloride
- Synonyms
- Daridorexant HCl;Nemorexant hydrochloride;Namoresen hydrochloride;Dalirasen hydrochloride;Daridorexant hydrochlorid;Daridorexant hydrochloride;Nemorexant hydrochloride|||Quviviq;Daridorexant hydrochloride, 10 mM in DMSO;(S)-(2-(5-chloro-4-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin- 1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl);[(2S)-2-(5-chloro-4-methyl-1H-benzimidazol-2-yl)-2-methylpyrrolidin-1-yl]-[5-methoxy-2-(triazol-2-yl)phenyl]methanone
- CBNumber:
- CB04746931
- Molecular Formula:
- C23H24Cl2N6O2
- Molecular Weight:
- 487.39
- MDL Number:
- MOL File:
- 1792993-84-0.mol
- MSDS File:
- SDS
- TDS File:
- TDS
| InChIKey | HJVGDXBEMFHGKI-UUTVKYGWNA-N |
|---|---|
| SMILES | C[C@@]1(C2=NC3=CC=C(Cl)C(C)=C3N2)CCCN1C(C1C=C(OC)C=CC=1N1N=CC=N1)=O.Cl |&1:1,r| |
| FDA UNII | 9X9581N56R |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|---|---|
| Signal word | Warning |
| Hazard statements | H302-H315-H319-H335 |
| Hazard statements | H413 |
| Precautionary statements | P280-P305+P351+P338 |
Daridorexant hydrochloride price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Biosynth | FD00147 | Daridorexant hydrochloride | 1792993-84-0 | 5mg | $275 | 2026-06-04 | Buy |
| Biosynth | FD00147 | Daridorexant hydrochloride | 1792993-84-0 | 10mg | $412.5 | 2026-06-04 | Buy |
| Biosynth | FD00147 | Daridorexant hydrochloride | 1792993-84-0 | 25mg | $859.5 | 2026-06-04 | Buy |
| Biosynth | FD00147 | Daridorexant hydrochloride | 1792993-84-0 | 50mg | $1375 | 2026-06-04 | Buy |
| Biosynth | FD00147 | Daridorexant hydrochloride | 1792993-84-0 | 100mg | $1925 | 2026-06-04 | Buy |
Daridorexant hydrochloride Chemical Properties, Uses, Production
Description
Daridorexant hydrochloride is a small molecule drug with a maximum clinical trial phase of IV that was first approved in 2022 and is indicated for insomnia.
Uses
Daridorexant hydrochloride is a novel dual orexin receptor antagonist indicated for the treatment of adult patients with insomnia. By selectively targeting both orexin receptors, Daridorexant blocks the action of orexin (also known as hypocretin), a neuropeptide that regulates wakefulness.
References
[1] VAN GINNEKEN V, SAUTER C. Daridorexant: a new treatment option for delayed sleep phase disorder (DSPD)[J]. ACS Applied Electronic Materials, 2024, 734. DOI:10.1016/j.sleep.2023.11.177.
[2] Daridorexant Hydrochloride.[J]. American Journal of Health-System Pharmacy, 2022, 21 1. DOI:10.1093/ajhp/zxac137.
[3] https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Daridorexant_%28drug%29.pdf
